Equities Analysts Set Expectations for Enhabit Q4 Earnings

Enhabit, Inc. (NYSE:EHAB) – Research analysts at Leerink Partnrs upped their Q4 2025 earnings per share (EPS) estimates for shares of Enhabit in a report issued on Monday, November 18th. Leerink Partnrs analyst W. Mayo now expects that the company will post earnings of $0.08 per share for the quarter, up from their previous estimate of $0.05. The consensus estimate for Enhabit’s current full-year earnings is $0.25 per share.

Separately, Leerink Partners reiterated a “market perform” rating and set a $8.00 price target (down from $8.50) on shares of Enhabit in a report on Tuesday. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $9.25.

Enhabit Stock Up 1.8 %

Shares of Enhabit stock opened at $7.27 on Wednesday. The stock has a market capitalization of $365.31 million, a P/E ratio of -3.13 and a beta of 1.84. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85. The stock has a 50 day moving average price of $7.54 and a two-hundred day moving average price of $8.43. Enhabit has a 12-month low of $6.85 and a 12-month high of $11.74.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The firm had revenue of $253.60 million during the quarter, compared to the consensus estimate of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same period in the previous year, the firm posted $0.03 EPS.

Insider Activity

In other news, Director Jeffrey Bolton acquired 5,000 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average cost of $8.01 per share, for a total transaction of $40,050.00. Following the completion of the transaction, the director now directly owns 78,877 shares in the company, valued at $631,804.77. This trade represents a 6.77 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Enhabit

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EHAB. DekaBank Deutsche Girozentrale boosted its holdings in Enhabit by 39.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 340,412 shares of the company’s stock worth $3,861,000 after buying an additional 95,488 shares during the last quarter. WINTON GROUP Ltd bought a new position in Enhabit during the second quarter worth about $955,000. Marshall Wace LLP bought a new position in Enhabit during the second quarter worth about $1,941,000. Orion Portfolio Solutions LLC boosted its holdings in Enhabit by 72.5% during the first quarter. Orion Portfolio Solutions LLC now owns 96,833 shares of the company’s stock worth $1,128,000 after buying an additional 40,684 shares during the last quarter. Finally, AREX Capital Management LP lifted its holdings in shares of Enhabit by 2.5% during the 2nd quarter. AREX Capital Management LP now owns 2,472,662 shares of the company’s stock valued at $22,056,000 after purchasing an additional 59,353 shares in the last quarter.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.